Skip to Content

Telix Pharmaceuticals Ltd Ordinary Shares TLX

Morningstar Rating
A$18.73 +0.45 (2.46%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

TLX is trading within a range we consider fairly valued.
Price
A$18.42
Fair Value
A$19.59
Uncertainty
High
1-Star Price
A$46.97
5-Star Price
A$56.45
Economic Moat
Vrbh
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TLX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
A$18.28
Day Range
A$18.1218.73
52-Week Range
A$8.2019.06
Bid/Ask
A$18.71 / A$18.73
Market Cap
A$6.25 Bil
Volume/Avg
461,427 / 1.2 Mil

Key Statistics

Price/Earnings (Normalized)
143.93
Price/Sales
11.75
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney), and glioblastoma (brain) cancer. Geographically, It operates through two reportable segments Commercial operations which include Commercial sales of Illuccix® and other products after obtaining regulatory approvals and Product development includes Developing radiopharmaceutical products for commercialisation. This segment includes revenue received from license agreements before commercialization and research and development services. It operates in Australia, the United States, Belgium, and Japan.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Mid Growth
Total Number of Employees

Comparables

Valuation

Metric
TLX
NYKD
ICVX
Price/Earnings (Normalized)
143.93
Price/Book Value
39.742.703.30
Price/Sales
11.7539.04
Price/Cash Flow
244.29
Price/Earnings
TLX
NYKD
ICVX

Financial Strength

Metric
TLX
NYKD
ICVX
Quick Ratio
1.198.4317.59
Current Ratio
1.438.4318.06
Interest Coverage
1.15
Quick Ratio
TLX
NYKD
ICVX

Profitability

Metric
TLX
NYKD
ICVX
Return on Assets (Normalized)
3.71%−18.26%−29.30%
Return on Equity (Normalized)
11.73%−23.64%−31.87%
Return on Invested Capital (Normalized)
18.08%−26.98%−34.69%
Return on Assets
TLX
NYKD
ICVX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
PqnpxcxqpbKwgxg$631.5 Bil
Vertex Pharmaceuticals Inc
VRTX
GjmjbmkmJjyxsm$122.6 Bil
Regeneron Pharmaceuticals Inc
REGN
JhgyrjmHmykxff$117.3 Bil
Moderna Inc
MRNA
CngwsfrylRxpds$52.5 Bil
Alnylam Pharmaceuticals Inc
ALNY
CwmqcmnjJjpxl$28.2 Bil
argenx SE ADR
ARGX
BtdzmsvrzBmj$23.7 Bil
BioNTech SE ADR
BNTX
HswbxdhmVfqn$20.9 Bil
Biomarin Pharmaceutical Inc
BMRN
WrprzzvyZrrtvq$16.2 Bil
United Therapeutics Corp
UTHR
QmvppspMljfg$14.1 Bil
Incyte Corp
INCY
DrbpszbdKfzjs$12.6 Bil

Sponsor Center